About N-arachidonyl glycine receptor
N-arachidonyl glycine receptor (GPR18) is a protein
from Homo sapiens identified by UniProt accession
Q14330, 331 residues long.
MolForge cross-references it against 0 known binders and
140 disease associations.
Target properties
| Protein name | N-arachidonyl glycine receptor |
|---|
| UniProt accession | Q14330 |
|---|
| Gene | GPR18 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 331 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (140)
Diseases linked to this target (Open Targets).
- Crohn's disease · score 0.29
- inflammatory bowel disease · score 0.26
- hypothyroidism · score 0.25
- asthma · score 0.24
- basal cell carcinoma · score 0.24
- childhood onset asthma · score 0.23
- thyroid disease · score 0.23
- atopic asthma · score 0.20
- psoriasis · score 0.17
- ulcerative colitis · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q14330-F1 | alphafold | PREDICTED | 86.31 | — |
Amino-acid sequence (331 residues)
MITLNNQDQP VPFNSSHPDE YKIAALVFYS CIFIIGLFVN ITALWVFSCT TKKRTTVTIY MMNVALVDLI FIMTLPFRMF YYAKDEWPFG EYFCQILGAL TVFYPSIALW LLAFISADRY MAIVQPKYAK ELKNTCKAVL ACVGVWIMTL TTTTPLLLLY KDPDKDSTPA TCLKISDIIY LKAVNVLNLT RLTFFFLIPL FIMIGCYLVI IHNLLHGRTS KLKPKVKEKS IRIIITLLVQ VLVCFMPFHI CFAFLMLGTG ENSYNPWGAF TTFLMNLSTC LDVILYYIVS KQFQARVISV MLYRNYLRSM RRKSFRSGSL RSLSNINSEM L
Explore N-arachidonyl glycine receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets